Active Ingredient History

NOW
  • Now
Riluzole, a member of the benzothiazole class, is indicated for the treatment of patients with amyotrophic lateral sclerosis. Its pharmacological properties include the following, some of which may be related to its effect: 1) an inhibitory effect on glutamate release (activation of glutamate reuptake), 2) inactivation of voltage-dependent sodium channels, and 3) ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors. Common adverse reactions include headache, abdominal pain, back pain, vomiting, dyspepsia, diarrhea, dizziness. Riluzole-treated patients that take other hepatotoxic drugs may be at increased risk for hepatotoxicity.   NCATS

  • SMILES: NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2
  • InChIKey: FTALBRSUTCGOEG-UHFFFAOYSA-N
  • Mol. Mass: 234.198
  • ALogP: 2.78
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

United States

$0.6232 - $1415.2600

Australia

$2.6557 - $87.6399
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

6-trifluoromethoxybenzothiazol-2-ylamine | rilutek | rilutor | riluzol | riluzole | riluzole hcl | riluzole hydrochloride | riluzolum | rp54274 | rp-54274 | teglutik

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue